An update to the Diabetes Canada guidelines includes the option of adding SGLT2 inhibitors to metformin or to a sulfonylurea plus metformin if glycemic targets are not met (Goldenberg et al., 2016). Here, SLC5A2 is linked to diabetes mellitus.